Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 34
Filter
4.
Clin Endocrinol (Oxf) ; 55(3): 325-30, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11589675

ABSTRACT

OBJECTIVE: Plasma levels of dehydroepiandrosterone sulphate (DHEA-S) decrease with the progression of HIV disease. Here, we report on the efficacy and safety of the oral administration of DHEA as replacement therapy, in patients with advanced HIV disease, in a trial that was primarily aimed at assessing quality of life. DESIGN: The trial was randomized and double-blind. Thirty-two patients were allocated to either DHEA 50 mg per day for 4 months (n = 14) or a matching placebo (n = 18). Clinical data, virological and immunological surrogate markers of HIV infection, plasma levels of DHEA-S and the Medical Outcomes Study HIV Health Survey (MOS-HIV) quality of life scale were recorded every month. RESULTS: The mean age of the patients was 40 +/- 11 years. The mean CD4 cell count at baseline was 32.5 +/- 32.4 x 10(6)/l. The mean DHEA-S plasma level at baseline was 5.23 +/- 0.76 micromol/l. No side-effects related to DHEA occurred during the study. A statistically significant increase in the levels of DHEA-S was observed in the treated group throughout the study (P < 0.01). A significant improvement in the Mental Health and Health Distress dimension of MOS-HIV was observed in the DHEA treated group; P = 0.001 and 0.004, respectively. No change in CD4 cell counts was seen during follow-up. CONCLUSIONS: The administration of DHEA in patients with advanced HIV infection results in improved mental function scores as assessed by the MOS-HIV quality of life scale.


Subject(s)
Dehydroepiandrosterone Sulfate/blood , Dehydroepiandrosterone Sulfate/therapeutic use , HIV Infections/blood , HIV-1 , Hormone Replacement Therapy , Adult , Double-Blind Method , Female , Follow-Up Studies , HIV Infections/psychology , Health Status Indicators , Humans , Male , Middle Aged , Prospective Studies , Psychometrics , Quality of Life
6.
AIDS ; 13(11): F71-7, 1999 Jul 30.
Article in English | MEDLINE | ID: mdl-10449277

ABSTRACT

OBJECTIVE: to assess the safety and efficacy of a combination of ritonavir, efavirenz and two recycled nucleosides in patients who failed on a conventional triple-drug regimen including indinavir or ritonavir. METHODS: An open label study of ritonavir (100 mg twice daily), saquinavir (1000 mg twice daily), efavirenz (600 mg per day) and nucleoside analogues in 32 saquinavir- and efavirenz-naive protease inhibitor-experienced patients. Patients were included on the basis of plasma levels of HIV RNA above 5000 copies/ml while on conventional antiretroviral therapy. Phenotypic resistance and genotypic resistance mutations to saquinavir were assessed at baseline. Peak and trough plasma levels of saquinavir were monitored throughout the study. RESULTS: Median CD4 cell counts and median plasma HIV RNA at baseline were 258 x 10(6)/l and 4.31 log10 copies/ml, respectively. The plasma viral load decreased by a median of 1.20 log10 copies/ml and the CD4 cell count increased by a median 60 x 10(6) cells/l at week 24 of therapy. Seventy-one per cent of the patients achieved a plasma viral load < 500 copies/ml and 45% achieved a viral load < 50 copies/ml. Patients exhibiting phenotypic resistance to saquinavir at baseline experienced a median decrease in HIV RNA of 0.91 log10 copies/ml at week 24 of therapy, as compared with a decrease of 1.52 log10 copies/ml in those exhibiting sensitive viral strains (P = 0.03). Genotypic resistance to saquinavir was not predictive of virologic failure. CONCLUSION: Our results indicate that the combination of ritonavir, saquinavir and efavirenz is safe and effective at 24 weeks in over two-thirds of patients who previously failed on highly active antiretroviral therapy, and that the determination of phenotypic resistance may be of greater value than the detection of resistance mutations to predict the outcome of salvage therapy in this setting.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Protease Inhibitors/pharmacology , HIV-1/drug effects , Saquinavir/pharmacology , Adult , Alkynes , Benzoxazines , CD4 Lymphocyte Count , Cyclopropanes , Drug Resistance, Microbial , Drug Therapy, Combination , Female , HIV Infections/virology , HIV Protease/genetics , HIV Protease Inhibitors/therapeutic use , HIV-1/genetics , HIV-1/physiology , Humans , Male , Middle Aged , Mutation , Oxazines/therapeutic use , RNA, Viral/blood , Reverse Transcriptase Inhibitors/therapeutic use , Ritonavir/therapeutic use , Saquinavir/pharmacokinetics , Saquinavir/therapeutic use , Treatment Outcome
7.
AIDS ; 12(7): 745-50, 1998 May 07.
Article in English | MEDLINE | ID: mdl-9619806

ABSTRACT

OBJECTIVES: To determine the clinical, virological and immunological outcome in a cohort of unselected patients receiving triple combination therapy for more than 1 year. METHODS: Prospective follow-up of a cohort of 162 unselected, protease inhibitor-naive, antiretroviral-experienced patients with advanced HIV disease, treated with indinavir combined with two nucleoside analogues. RESULTS: The mean CD4 cell count and plasma HIV RNA level in the study group at baseline were 69+/-5 x 10(6)/l and 4.75+/-0.07 log10 copies/ml, respectively. Five per cent of patients died prematurely or were lost to follow-up. Fifty-seven per cent of patients responded to therapy, as assessed by a sustained increase in CD4 cell counts above 50 x 10(6)/l and a decrease in plasma HIV RNA greater than 1 log10 copies/ml, throughout 12.1 months of follow-up. Seventeen per cent of patients were immunological and virological non-responders. Twenty-one per cent of patients exhibited discrepant virological and immunological responses to treatment, of whom one-half failed to exhibit significant increases in CD4 cells despite a virological response to therapy and one-half exhibited increased CD4 cell counts in the absence of significant decrease in plasma viral load. The incidence of AIDS-defining events in the latter group of patients was similar to that of responder patients, whereas their incidence was higher in patients who failed to exhibit a virological and immunological response and those who failed to increase CD4 cells despite a significant decrease in viral load. CONCLUSION: Our observations of discrepant immunological and virological responses to treatment raise the issue of the significance of persistent elevated levels of plasma HIV RNA and of the relevance of measurements of plasma viral load for assessing the efficacy of antiretroviral therapy in patients whose CD4 cell counts increase despite the absence of significant decrease in plasma HIV viral load.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , Indinavir/therapeutic use , Lamivudine/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Stavudine/therapeutic use , Zidovudine/therapeutic use , Adult , Aged , Cohort Studies , Drug Therapy, Combination , Female , Follow-Up Studies , HIV Infections/immunology , HIV Infections/physiopathology , HIV Infections/virology , Humans , Male , Middle Aged , Prospective Studies , Treatment Outcome
8.
Lancet ; 351(9095): 14-8, 1998 Jan 03.
Article in English | MEDLINE | ID: mdl-9433423

ABSTRACT

BACKGROUND: Despite multiple exposures to HIV-1, some individuals remain uninfected, and their peripheral-blood mononuclear cells (PBMC) are resistant to in-vitro infection by primary HIV-1 isolates. Such resistance has been associated with a homozygous 32-base-pair deletion (delta 32) in the C-C chemokine receptor gene CCR5. We examined other mutations of the CCR5 gene that could be associated with resistance to HIV-1 infection. METHODS: We assessed the susceptibility of PBMC to in-vitro infection by HIV-1 isolates that use the CCR5 as the major coreceptor for viral entry in 18 men who had frequent unprotected sexual intercourse with a seropositive partner. We also did genotypic analysis of CCR5 alleles. One of the 18 exposed but uninfected men (who we refer to as ExU2) showed total resistance to in-vitro infection by CCR5-dependent viruses, and was found to carry a CCR5 delta 32 allele and a single point mutation (T-->A) at position 303 on the other allele. To find out whether the CCR5 mutation was restricted to ExU2's family or existed in the general population, we did genetic analyses of the CCR5 genotype in ExU2's father and sister and also in 209 healthy blood donors who were not exposed to HIV-1. FINDINGS: The m303 mutation found in ExU2 introduced a premature stop codon and prevented the expression of a functional coreceptor. The family studies revealed that the m303 mutant allele was inherited as a single mendelian trait. Genotype analysis showed that three of the 209 healthy blood donors were heterozygous for the mutant allele. INTERPRETATION: We characterise a new CCR5 gene mutation, present in the general population, that prevents expression of functional coreceptors from the abnormal allele and confers resistance to HIV-1 infection when associated to the delta 32 CCR5 mutant gene.


Subject(s)
Acquired Immunodeficiency Syndrome/genetics , HIV-1 , Mutation , Receptors, CCR5/genetics , Acquired Immunodeficiency Syndrome/immunology , Acquired Immunodeficiency Syndrome/transmission , Base Sequence , Female , HIV-1/immunology , Humans , Immunity, Innate/genetics , In Vitro Techniques , Leukocytes, Mononuclear/virology , Male , Phenotype , Polymerase Chain Reaction , Sequence Deletion
10.
J Acquir Immune Defic Syndr Hum Retrovirol ; 13(2): 146-54, 1996 Oct 01.
Article in English | MEDLINE | ID: mdl-8862279

ABSTRACT

We report on a retrospective study evaluating infectious morbidity associated with totally implantable venous access devices (TIVAD) (Port-A-Cath) in HIV-infected patients. This study of 84 consecutive HIV-infected patients requiring 89 TIVAD between January 1990 and October 1993 was performed in the Department of Infectious Diseases Hôpital de l'Institut Pasteur, Paris, France. The total number of catheter days was 11,595. Eighteen of 89 patients with TIVAD (20%) were infected, causing 25 infectious events (25/89: 28%) among 17 different patients (17/84: 20%). The infection rate was 0.22 per 100 catheter days. Mean onset of infection was 82 days. Twenty microorganisms were isolated: Staphylococcus aureus in eight cases (40%), coagulase-negative Staphylococcus in six cases (30%), Streptococcus D faecalis in one case; Gram-negative bacilli were found in five cases (25%). All patients received an intravenous antibiotherapy combined with a local lock treatment in eight cases. Nine TIVAD removals were performed. One death was related to the TIVAD infection. No additional predisposing factor for infection was identified other than the implied condition of the HIV infection. The population and material in this study were homogeneous. The TIVAD infection rate was comparable to other published reports. Prospective evaluation comparing tunneled catheter and TIVAD in HIV-infected patients is needed.


Subject(s)
Bacteremia/diagnosis , Catheterization, Central Venous/adverse effects , HIV Infections/therapy , Adult , Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Bacteremia/epidemiology , Bacteremia/mortality , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Time Factors
11.
Clin Infect Dis ; 22(4): 626-31, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8729200

ABSTRACT

We reviewed cases of cytomegalovirus (CMV) infection of the central nervous system (CNS) that initially masqueraded as tumors in 37 of 543 consecutive patients infected with human immunodeficiency virus (HIV) and CMV who were seen at the Pasteur Institute Hospital and Saint-Louis Hospital (Paris) between 1992 and 1994. We detail the clinical features of three patients who presented with ring-enhanced space-occupying lesions mimicking CNS tumors. They were all profoundly immunodepressed (mean CD4 cell count, 13/mm3). Magnetic resonance imaging (MRI) showed enlargement of the spinal cord in one case, consistent with a space-occupying lesion and showing gadolinium enhancement; in the other two cases, ring-enhanced mass lesions were seen in the cerebral hemispheres. In all three cases marked edema and a mass effect were present. Image-guided stereotactic biopsies confirmed the diagnosis of CMV infection. The three patients' conditions improved with specific therapy. MRI showed enhanced focal intraparenchymal lesions consistent with marked focal necrosis, probably related to the severity of immunodepression, as HIV infection had been diagnosed several years previously. CMV infection should be considered as a cause of ring-enhanced space-occupying mass lesions in patients with HIV-1 infection. Earlier identification of these unusual tumorlike forms of CMV infection by means of MRI should result in improved outcome.


Subject(s)
AIDS-Related Opportunistic Infections/diagnosis , Acquired Immunodeficiency Syndrome/complications , Brain Neoplasms/diagnosis , Cytomegalovirus Infections/diagnosis , Spinal Cord Neoplasms/diagnosis , AIDS-Related Opportunistic Infections/virology , Adult , Brain Neoplasms/diagnostic imaging , Cytomegalovirus Infections/complications , Cytomegalovirus Infections/drug therapy , Diagnosis, Differential , Encephalitis, Viral/diagnosis , Encephalitis, Viral/diagnostic imaging , Encephalitis, Viral/drug therapy , Encephalitis, Viral/virology , Humans , Magnetic Resonance Imaging , Male , Myelitis/diagnosis , Myelitis/diagnostic imaging , Myelitis/drug therapy , Myelitis/virology , Radiography , Retrospective Studies , Spinal Cord Neoplasms/diagnostic imaging
13.
AIDS Res Hum Retroviruses ; 11(3): 373-81, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7598771

ABSTRACT

The safety and the immunogenicity of a recombinant canarypox live vector expressing the human immunodeficiency virus type 1 (HIV-1) gp160 gene from the MN isolate, ALVAC-HIV (vCP125), followed by booster injections of a soluble recombinant hybrid envelope glycoprotein MN/LAI (rgp160), were evaluated in vaccinia-immune, healthy adults at low risk for acquiring HIV-1 infection. Volunteers (n = 20) received vCP125 (10(6) TCID50) at 0 and 1 month, followed randomly by rgp160 formulated in alum or in Freund's incomplete adjuvant (FIA) at 3 and 6 months. Local and systemic reactions were mild or moderate and resolved within the first 72 hr after immunization. No significant biological changes in routine tests were observed in any volunteer. Two injections of vCP125 did not elicit antibodies. Neutralizing antibodies (NA) against the HIV-1 MN isolate were detected in 65 and 90% of the subjects after the first and the second rgp 160 booster injections, respectively. Six months after the last boost, only 55% were still positive. Seven of 14 sera with the highest NA titers against MN weakly cross-neutralized the HIV-1 SF2 isolate; none had NA against the HIV-1 LAI or against a North American primary isolate. Specific lymphocyte T cell proliferation to rgp 160 was detected in 25% of the subjects after vCP125 and in all subjects after the first booster injection and 12 months after the first injection. An envelope-specific cytotoxic lymphocyte activity was found in 39% of the volunteers and characterized for some of them as CD3+, CD8+, MHC class I restricted. The adjuvant formulation did not influence significantly the immune responses.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
AIDS Vaccines/therapeutic use , Acquired Immunodeficiency Syndrome/prevention & control , Gene Products, env/immunology , HIV Antibodies/blood , HIV Infections/prevention & control , HIV Seronegativity , Immunization, Secondary , Protein Precursors/immunology , Vaccines, Synthetic/therapeutic use , AIDS Vaccines/adverse effects , Acquired Immunodeficiency Syndrome/immunology , Adult , Animals , Avipoxvirus/immunology , CD4 Lymphocyte Count , CD4-CD8 Ratio , CD8-Positive T-Lymphocytes/immunology , Canaries , Enzyme-Linked Immunosorbent Assay , Female , Gene Products, env/adverse effects , HIV Envelope Protein gp160 , HIV Infections/immunology , Humans , Lymphocyte Count , Male , Middle Aged , Protein Precursors/adverse effects , Time Factors , Vaccines, Synthetic/adverse effects
17.
Clin Infect Dis ; 16(3): 441-2, 1993 Mar.
Article in English | MEDLINE | ID: mdl-8452957

ABSTRACT

Two cases of rhinoscleroma in patients infected with the human immunodeficiency virus (HIV) who had stayed in an area of endemic Klebsiella rhinoscleromatis are reported. One of the patients presented with oropharyngeal lesions, an unusual clinical picture. Both patients suffered from a major cellular immune deficiency. The importance of Klebsiella rhinoscleromatis infection in AIDS-related oropharyngeal pathology and the possible treatment of such infection in HIV-positive patients are not yet clearly established.


Subject(s)
AIDS-Related Opportunistic Infections , Acquired Immunodeficiency Syndrome/complications , Rhinoscleroma , AIDS-Related Opportunistic Infections/drug therapy , Adult , Follow-Up Studies , Humans , Klebsiella , Male , Oropharynx/pathology , Rhinoscleroma/complications , Rhinoscleroma/drug therapy , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use
18.
Am J Clin Oncol ; 15(1): 7-11, 1992 Feb.
Article in English | MEDLINE | ID: mdl-1550083

ABSTRACT

We studied survival in 36 patients with Stage III/IV ovarian cancer who received intraperitoneal high-dose cisplatin (200 mg/m2) alone or in combination with cytarabine (2 g), after intravenous (i.v.) cisplatin-based chemotherapy followed by second-look laparotomy. Complete responders were scheduled for three courses of IP chemotherapy, and others for six. Eight patients (22%) did not complete treatment (6 catheter failures and 2 renal failures). Peritoneal cytology remained positive in 6 patients (17%). Median overall and progression-free survival after second-look laparotomy were 44 and 37 months, respectively, for 13 complete responders to i.v. chemotherapy; 24 months and 11 months for patients with residual tumors less than 2 cm (17 cases); 15 and 12 months with tumors greater than 2 cm (6 cases). There was a significant difference in overall (p = 0.05) and progression-free (p = 0.001) survival between complete responders to i.v. chemotherapy and patients whose tumor was less than 2 cm. We find no evidence that high-dose cisplatin-based intraperitoneal chemotherapy given after second-look laparotomy will enhance survival in advanced ovarian cancer with zero or minimal residual disease.


Subject(s)
Cisplatin/administration & dosage , Ovarian Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/adverse effects , Combined Modality Therapy , Cytarabine/administration & dosage , Female , Humans , Infusions, Parenteral , Ovarian Neoplasms/surgery , Reoperation , Survival Analysis
19.
Ann Oncol ; 2(3): 229-30, 1991 Mar.
Article in English | MEDLINE | ID: mdl-2043494

ABSTRACT

Twenty-five patients with advanced measurable gastric cancer were treated with high-dose folinic acid (200 mg/m2), 5-fluorouracil bolus (400 mg/m2) and continuous infusion (600 mg/m2) for two consecutive days every two weeks. Fourteen patients over 65 yr old and/or with a poor general status received first-line treatment, and eleven younger patients second-line. The response rate was 43.5% in 23 evaluable patients. There were 2 complete responses (8.7%) and 8 partial responses (34.8%). Median survival was 6 months in first-line and 8 months, calculated from start of folinic acid-5FU, in second-line. Toxicity was mild without WHO Grade greater than 2 events. This combination is effective for advanced gastric cancer in poor-prognosis patients and requires further studies.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Stomach Neoplasms/drug therapy , Adenocarcinoma/mortality , Adenocarcinoma/secondary , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Female , Fluorouracil/administration & dosage , Humans , Infusions, Intravenous , Leucovorin/administration & dosage , Liver Neoplasms/secondary , Lymphatic Metastasis , Male , Middle Aged , Ovarian Neoplasms/secondary , Peritoneal Neoplasms/secondary , Prognosis , Stomach Neoplasms/mortality
20.
Cancer Genet Cytogenet ; 52(1): 123-9, 1991 Mar.
Article in English | MEDLINE | ID: mdl-2009507

ABSTRACT

Plasma cell leukemia (PCL) is a very rare disease. We report two cases of PCL with complex chromosomal abnormalities: long arm trisomy and short arm partial monosomy of chromosome 1, a marker derived from chromosome 8, and monosomy 13 were found in both cases; other additional chromosome abnormalities were also present in each case. Bastard et al. reports two similar cases in this issue. Cytogenetic studies in PCL have seldom been reported in the literature: chromosomal abnormalities are most often complex: chromosomes 1, 8, 11, 13, and 14 are those most frequently involved. Such cytogenetic findings are observed in advanced multiple myeloma. Cytogenetic, clinical, and immunological findings observed in PCL and the advanced stage of multiple myeloma are arguments for the single origin of pathogenesis.


Subject(s)
Leukemia, Plasma Cell/genetics , Monosomy , Trisomy , Adult , Chromosomes, Human, Pair 1 , Chromosomes, Human, Pair 11 , Chromosomes, Human, Pair 13 , Chromosomes, Human, Pair 14 , Chromosomes, Human, Pair 8 , Female , Humans , Karyotyping
SELECTION OF CITATIONS
SEARCH DETAIL
...